Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ascorbate-Meglumine for Brain Metastases SRS
NCT06433791Phase 1Enrolling by invitation
- Start
- Sep 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ascorbate-meglumine in brain metastases (4 arms). Primary endpoint: Safety as measured by adverse events. Started Sep 2024; status: enrolling by invitation.
02
Drugs
ascorbate-meglumine
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT06433791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06433791.